About actinium pharmaceuticals inc - ATNM
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, discovery, and clinical development of targeted radiotherapies. It also develops and markets medicines for relapsed and refractory cancer patients. The company was founded in 2000 and is headquartered in New York, NY.
ATNM At a Glance
Actinium Pharmaceuticals, Inc.
100 Park Avenue
New York, New York 10017
| Phone | 1-646-677-3870 | Revenue | 90.00K | |
| Industry | Pharmaceuticals: Major | Net Income | -33,887,000.00 | |
| Sector | Health Technology | Employees | 25 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
ATNM Valuation
| P/E Current | 2.888 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 471.405 |
| Price to Book Ratio | 5.416 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.109 |
| Enterprise Value to Sales | -43.084 |
| Total Debt to Enterprise Value | -0.437 |
ATNM Efficiency
| Revenue/Employee | 3,600.00 |
| Income Per Employee | -1,355,480.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.001 |
ATNM Liquidity
| Current Ratio | 6.197 |
| Quick Ratio | 6.197 |
| Cash Ratio | 6.023 |
ATNM Profitability
| Gross Margin | -812.222 |
| Operating Margin | -40,274.444 |
| Pretax Margin | -37,652.222 |
| Net Margin | -37,652.222 |
| Return on Assets | -52.495 |
| Return on Equity | -166.964 |
| Return on Total Capital | -355.657 |
| Return on Invested Capital | -159.255 |
ATNM Capital Structure
| Total Debt to Total Equity | 21.624 |
| Total Debt to Total Capital | 17.779 |
| Total Debt to Total Assets | 3.245 |
| Long-Term Debt to Equity | 12.407 |
| Long-Term Debt to Total Capital | 10.202 |